Overview

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Status:
RECRUITING

Trial end date:
2027-04-20

Target enrollment:

Participant gender:

Summary

This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of Cadonilimab(AK104) in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Phase:

PHASE2

Details

Lead Sponsor:

Hunan Cancer Hospital

Treatments:

lenvatinib